Trial reportJournal of cosmetic dermatology2025
Efficacy and Safety of an Oral Low-Dose Water-Dispersible Turmeric Extract Capsule on Facial Skin Health in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe role of turmeric extract (oral and topical) has been studied in the management of various skin disorders, but its potential to improve skin health in healthy individuals remains largely unexplored.
aimTo evaluate the efficacy and safety of an orally administered low-dose, water-dispersible turmeric extract containing 60% natural curcuminoids (WDTE60N) in reducing blemish and enhancing skin tone evenness, hydration, and gloss in healthy women.
methodsIn this double-blind, randomized, placebo-controlled trial, women (18-40 years) with one identified facial blemish were randomized to receive WDTE60N (250 mg) or a placebo capsule once daily for 60 days. Changes in a pre-marked blemish area on facial skin, skin hydration, transepidermal water loss (TEWL), and skin gloss from baseline to day 60 were evaluated.
resultsOf 96 participants enrolled, 90 (WDTE60N, n = 45; placebo, n = 45) completed the study. The WDTE60N group showed significantly greater reductions in Antera 3D imaging readings for blemish from baseline compared to placebo starting from day 30 (p = 0.036) onwards to day 60 (p = 0.001). Significant improvement from baseline in blemish scale score on day 30 (p = 0.024) and day 60 (p = 0.001) was observed in the WDTE60N group than in the placebo group. From day 15 onward, the WDTE60N administration significantly improved skin hydration and gloss while significantly reducing TEWL (p = 0.001). WDTE60N was well tolerated with no major adverse events.
conclusionWDTE60N 250 mg capsule was safe and effective in improving facial skin health in the participants. This study provides clinical evidence supporting WDTE60N as a promising cosmeceutical agent.
trial registrationCTRI number: CTRI/2024/06/068637.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.